Clinical Trials on Unresectable Hepatocellular Carcinoma in China

Total 5222 results

Zhongda Hospital

Recruiting

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Yue Han
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Unresectable Hepatocellular Carcinoma

China
Guangzhou University of Chinese Medicine

Completed

Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

Unresectable Hepatocellular Carcinoma

China
Wen Li

Recruiting

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Sun Yat-sen University
Xiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaborators

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage

China
Second Affiliated Hospital of Guangzhou Medical...
First Affiliated Hospital, Sun Yat-Sen University; First People's Hospital... and other collaborators

Recruiting

DEB-TACE+HAIC vs. HAIC for Large HCC

Unresectable Hepatocellular Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

Unresectable Hepatocellular Carcinoma (HCC)

China
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
Cancer Hospital of Guangxi Medical University

Active, not recruiting

Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma

TACE | Lenvatinib | Tislelizumab | Advanced Unresectable Hepatocellular Carcinoma

China
Fudan University

Unknown

Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma

Hepatocellular Carcinoma | Unresectable

China
BeiGene

Completed

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Hepatocellular Carcinoma | Unresectable Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma

China
Akeso

Recruiting

A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Unresectable, Non-metastatic Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Hepatocellular Carcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.

Recruiting

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-011)

Hepatocellular Carcinoma Non-resectable

China
Jinan Military General Hospital

Recruiting

The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Huazhong University of Science and Technology

Unknown

Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Affiliated Cancer Hospital & Institute of... and other collaborators

Recruiting

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Active, not recruiting

TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Hepatocellular Carcinoma Non-resectable

China
First Affiliated Hospital of Fujian Medical University

Recruiting

A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC

Hepatocellular Carcinoma Resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaborators

Active, not recruiting

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Hepatocellular Carcinoma Non-resectable

China
Xiangya Hospital of Central South University

Active, not recruiting

Thermal Ablation Followed by Immunotherapy for HCC

Hepatocellular Carcinoma Non-resectable

China
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital... and other collaborators

Unknown

Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Resectable Hepatocellular Carcinoma Beyond Milan Criteria

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
First Affiliated Hospital of Wenzhou Medical University
Qilu Hospital of Shandong University; Eastern Hepatobiliary Surgery Hospital; The First Affiliated Hospital of Zhejiang Chinese Medical University

Enrolling by invitation

Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)

Hepatocellular Carcinoma Non-resectable | Effect of Drug

China
Chengdu New Radiomedicine Technology Co. LTD.

Recruiting

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Tongji Hospital
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma (CCGLC-008)

Hepatocellular Carcinoma Non-resectable

China
Yongchang Zhang

Recruiting

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Huizhou Municipal Central Hospital; Zhongshan... and other collaborators

Completed

Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma Non-resectable

China
Bayer

Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery (REFINE-IO)

Unresectable Hepatocellular Carcinoma

Greece, Brazil, China, Colombia, Italy, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Thailand, United States, Argentina, France, Mexico, Turkey
Zhang Bi Xiang, MD

Recruiting

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma (CCGLC-003)

Hyperbaric Oxygen Therapy | Combinational Immunotherapy | Hepatocellular Carcinoma Non-Resectable

China
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
First Affiliated Hospital of Zhejiang University

Recruiting

SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

Unresectable Hepatocellular Carcinoma | Portal Vein Thrombosis

China
Sun Yat-sen University

Completed

Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion

Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Hepatocellular Carcinoma | Metastatic Cholangiocarcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular... and other conditions

United States

Clinical Trials on Unresectable Hepatocellular Carcinoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations